Qualcomm Arm Royalty Trial|Patent Licensor Seeking a 5-Year Royalty Halt?

A licensor on the paying side

Qualcomm has gone to trial against Arm in a Delaware federal court, seeking to stop paying Arm royalties for up to five years. That is an odd seat for a company one tech outlet calls the industry's most aggressive patent licensor. The same week, Huawei announced a patent cross-license with Qualcomm. Reports in Asia said Qualcomm would now pay Huawei more than Huawei pays Qualcomm.

Japan's Nikkei called it a de facto reversal of a fee flow that began in 2001. Put together, it looks like Qualcomm's royalty machine running in reverse. It should be read the other way around. The Huawei side is mostly a loss Qualcomm has already absorbed. The license that carries real risk for shareholders is the one Qualcomm pays for, from Arm. Qualcomm did not let the reversal story stand.

A spokesperson told Seeking Alpha the terms are confidential. Then the spokesperson added: “reports characterizing Qualcomm as a net payor on the license agreement are incorrect.” The spokesperson also said “assertions that the agreement is related to LogicFold are not accurate.” That refers to Huawei's new chip-stacking technique, which a Bloomberg report had tied to the deal.

Huawei's chief intellectual property officer, Alan Fan, described the same contract differently. He said it “demonstrates the value of Huawei's innovations.” Neither company disclosed the financial terms, so no outsider can yet say which way the net money runs. The history shows why that question matters less than it sounds. Huawei halted royalty payments to Qualcomm in 2018.

In 2020, it settled by agreeing to pay 1.8 billion dollars in back licensing fees. By early 2025, Huawei's license had expired. Qualcomm stopped counting Huawei royalties in its revenue in early 2025. So whichever way the payments now run, the Huawei income was already out of Qualcomm's numbers. What is new is a cost: Qualcomm agreed to buy certain non-cellular Huawei U.S. patents, at a price nobody has disclosed.

Even the November 4 earnings report won't show it. Qualcomm's fiscal year ended before the announcement, so the deal falls outside those results. On the collecting side, Apple renewed its global patent license with Qualcomm, effective April 1, 2027. For shareholders, the Huawei change is an undisclosed cost, not a new hole in revenue.

Where the risk moved

The hole Qualcomm does face sits in its chip sales. Apple probably accounts for about 7.5 billion dollars of Qualcomm's fiscal 2026 revenue. Management called that estimate a fair range. Qualcomm's revenue over the last twelve months was 44.1 billion dollars. So Apple is roughly 17 percent of the business.

In July, management said its share of the next iPhone would be “materially lower” than the 20 percent it had planned. It guided to a roughly 50 percent drop in Apple product revenue from September to December. Qualcomm's answer is the data center. It targets 5 billion dollars of data center revenue in fiscal 2027. By fiscal 2029, the goal is more than 15 billion dollars.

That 2029 target is about twice Apple's estimated fiscal 2026 contribution of 7.5 billion. The centerpiece is a server CPU called the Dragonfly C1000, with more than 250 Oryon cores. Amazon has signed on, with warrants tied to up to 60 billion dollars of purchases over ten years. This is where Arm comes in.

Qualcomm is one of Arm's largest customers, and Reuters describes their architecture agreement as a vital license. As Qualcomm's growth shifts toward CPUs, that license, in our reading, carries more weight than any Huawei patent deal.

The courtroom

Qualcomm's case centers on a moment in 2024. Qualcomm attorney Karen Dunn told the jury the company was on the cusp of a deal with Meta Platforms. Then Arm notified Qualcomm that it was in breach of its architecture agreement. Qualcomm alleges Arm leaked that letter to Bloomberg News. Dunn said Meta became concerned Qualcomm would lose its license.

By the time the deal closed, she said, its value had fallen by 170 million dollars. “Delay is costly,” she told the jury. Arm's attorney, Gregg LoCascio, offered another cause. He said Meta shifted to AI eyeglasses, away from virtual reality headsets, and sought to adjust financial terms. “They were not harmed in the least,” LoCascio said. Neither quote names the full prize.

Qualcomm also accuses Arm of withholding chip testing tools due under contract. And the remedy it seeks would let it stop paying Arm royalties for up to five years, potentially worth billions. Arm said Qualcomm accounted for 9 percent of its fiscal 2026 revenue. Reuters noted that a five-year hold could be a major sales impact for Arm. Arm denies breaching the contract. So the jury is weighing two things at once.

One is a cost line worth billions to Qualcomm. The other, in Dunn's telling, is whether doubts about Qualcomm's license can cost it customers. But the billions depend on something the jury may never get to decide. Judge Maryellen Noreika is considering whether to throw out that contractual remedy, Reuters reported. That could leave Qualcomm seeking a smaller damages claim.

Arm has argued Qualcomm's chip deals were speculative. And this is not the first round. Arm's earlier Nuvia lawsuit is a separate fight that remains under appeal. So the headline figure is the least settled part of this trial. If the remedy goes, the money in play shrinks toward claims like the 170 million dollars Dunn described.

The license for what comes next

A quieter proceeding runs alongside the jury. In a parallel bench trial, the judge alone will examine whether Arm negotiated in good faith with Qualcomm. The subject is the next version of Arm's chip technology. That question looks forward, not back. Damages settle what already happened. This one bears on the terms Qualcomm gets for Arm's next technology, just as its growth plan rests on CPUs.

And Arm is no longer only a licensor. It now has its own AGI CPU, a revenue stream alongside its licensing business. Chief Executive Rene Haas has pointed to 2 billion dollars in identified customer orders. Qualcomm, for its part, projects a CPU market of about 200 billion dollars by fiscal 2029 or 2030.

So the company that sets the terms of Qualcomm's license is now selling processors of its own, while Qualcomm chases that CPU spending. That narrows where the shareholder risk lives. It is not the Huawei check, and it may not be the jury's damages. It is the price and access Qualcomm gets for Arm's next technology, from a licensor that also has CPUs to sell.

Where it lands

Qualcomm's own history offers one guide to how such fights end. Apple began developing its own modems in 2017 to reduce its reliance on Qualcomm. Years of litigation followed, and analysts assumed Apple would cut ties when the license expired in 2027. Instead, the two extended the license, effective the very day it was set to expire. The roles here are reversed: Qualcomm is the licensee, and Arm owns the architecture.

If that pattern holds, the likelier end is a negotiated license, with the fight over its price. So back to the opening picture: a patent licensor fighting to stop paying royalties, while headlines say it now pays Huawei. The Huawei side is an undisclosed cost on income that was already gone. The weight falls on Arm, and more on the terms for Arm's next technology than on this jury's damages.

The first sign this read is wrong would be Judge Noreika's ruling on the five-year royalty remedy. If it stays in the case and the jury grants it, the damages become the main story. Qualcomm would then keep billions in royalty payments for up to five years. Arm would lose payments from a customer that made up 9 percent of its fiscal 2026 revenue.

Informational only, not investment advice. Figures and quotes come from the linked reports.